SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows post-earnings selloff is tied to an earnings miss and a softer outlook for contracted revenue growth, reviving concerns about slowing growth, valuation and AI disruption despite continued AI demand. Traders are split between calling the drop an overreaction and buying the dip, and seeing the weaker growth outlook as a warning sign.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated Phase 2 lung-cancer data, with a 24.6% overall response rate and stronger results in a small biomarker-selected subgroup, sparked a sharp selloff. Traders are split over whether the subgroup points to a promising precision-treatment path or a narrower opportunity and longer road to approval, while many criticize managements presentation of the results.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets quarterly results disappointed investors as Search and advertising growth slowed while heavy AI infrastructure spending pressured cash flow. Traders are divided between concerns that AI could erode Search monetization and the cost of investment, and dip-buyers pointing to strong Cloud growth and calling the selloff an overreaction.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

A weaker-than-expected quarterly report, slowing Search growth and heavy AI-related spending that pushed free cash flow negative sparked a steep selloff. Traders are divided between calling the drop an overreaction and buying on Google Clouds growth, versus worrying that AI search may be harder to monetize and cash generation could remain under pressure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings report is the dominant focus, with traders watching AWS growth, AI-related capital spending, cash flow and guidance. The community is split between optimism that strong cloud results could support the shares and concern that heavy spending could trigger a selloff like Alphabets reaction.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is in focus ahead of its quarterly earnings report, with traders split on whether results and guidance can reverse the stocks pre-report slide or trigger a further selloff. The debate is playing out amid weakness across chip stocks and concern that softer-than-expected spending by major cloud companies could weigh on AI infrastructure demand.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Anticipation around SanDisks quarterly earnings and guidance is driving attention, with traders focused on whether AI-related NAND and storage demand will support strong results. Bulls point to positive memory-sector signals, while bears worry that high expectations are already priced in and that shares could fall even on a strong report.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports that Marvell is in advanced talks to acquire Lumentum have driven attention, with traders focused on the potential deals financing, dilution and debt risks. Some see strategic value in securing scarce optical components for AI data centers, while others question the price and warn the talks remain unconfirmed and no deal is final.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Phase 3 REGAL trial reaching its 80th event triggered final analysis, putting the awaited topline survival results in focus. Bulls view the prolonged trial and survival timeline as encouraging and are buying dips, while skeptics stress that the event milestone reveals no treatment benefit and debate the risk ahead of the binary readout.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is selling off alongside semiconductor stocks as traders react to Samsungs profit miss and lower-than-expected Microsoft and Alphabet capital spending, raising concerns about the pace and returns of AI infrastructure investment. Bears focus on weak price action and sector-wide pressure, while bulls view the drop as a pullback and look to upcoming memory-sector earnings for direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallStPR NewswireNEW...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and...

BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action Pending

BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action Pending BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action PendingPR NewswireSAN FRANCISCO, Oct. 29...

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff DeadlinePR...

BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky

BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & KorsinskyPR NewswireNEW YORK...

What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud...

Beta Bionics (BBNX) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Beta Bionics Q3 2026 Earnings Call Transcript

Beta Bionics (NASDAQ:BBNX) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class...

$BBNX Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

Stocktwits

Beta Bionics Inc.

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

Beta Bionics reported larger operating losses, withdrew 3D Intelligences 510(k) application for additional simulator validation, and cited potential Q4 2026 revenue deferrals of up to $8.5M as prospective iLet users could await Mint.

Beta Bionics reported Q3 2026 net sales of $35.5M and PBP channel sales up 118%, received FDA clearance for Mint, completed type 2 pivotal-trial enrollment, and announced an Eversense integration agreement.

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral

Equity

Neutral Sentiment

Shares of Beta Bionics rose Thursday following the initiation of coverage by two Wall Street financial firms on the diabetes-focused medical technology company.Beta Bionics shares climbed 6.4% to close at $15.36 on Thursday, with an additional 0.8% gain in after-hours trading.Goldman Sachs assigned Beta Bionics a ‘Neutral’ rating with a $16 price target, as its technology targets a specific portion of the Type 1 diabetes market.&nbsp;Still, current consensus expectations already account for most of its immediate growth possibilities.&nbsp;According to analyst David Roman, Beta Bionics' current valuation reflects two key factors: its projected growth positions it to outperform diabetes peers and SMID-cap medtech firms in the near term.At the same time, the valuation also prices in the expected need for capital raises to reach cash flow breakeven.Meanwhile, Wolfe Research signaled optimism&nbsp;by initiating coverage with an ‘Outperform’ rating and a $20 price target.Beta Bionics created the iLet Bionic Pancreas device, which automates insulin delivery for individuals with Type 1 diabetes.Recently, the medical technology firm posted strong Q1 2025 results, with net sales growth of 36% year over year, bringing total sales to $17.6 million.&nbsp;The company saw growth through a 360% increase in Pharmacy Benefit Plan (PBP) channel sales and a 291% rise in the installed user base, reaching over 19,000.&nbsp;Operating losses rose to $18.6 million, resulting in a net loss of $28.7 million.Beta Bionics projects FY25 revenues between $82 and $87 million and gross margins between 50% and 53% while expecting a rise in new patient starts through the PBP channel.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.Beta Bionics stock has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, logos of Beta Bionics are displayed on mobile phone screen and computer screen in Ankara, Turkiye on September 5, 2023. (Photo by Arda Kucukkaya/Anadolu Agency via Getty Images)

Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.

$AMZN

$INTC

$RDDT

$SNDK

Which earnings release after the close will you be watching closest: $AMZN, $INTC, $RDDT, or $SNDK? 

Drop a comment for other tickers like $COIN, $SBUX, and $TWLO.

Current Price	$17.12
Prev Close	$17.85
Open	$17.78
Dividend Yield	0.00%
50-Day Moving Average	$19.21
Beta	1.53
Avg. Volume	1.52M
PE Ratio	-9.67

52-Week High	$32.71
52-Week Low	$8.80
Market Capitalization	$970.45M
EPS (Annual)	-$1.81
Price to Book	2.42
Revenue Per Employee	$237,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBNX Fundamentals